dc.contributor.author | Tangen, Jon-Magnus | |
dc.contributor.author | Tjønnfjord, Geir Erland | |
dc.contributor.author | Gulbrandsen, Nina | |
dc.contributor.author | Gedde-Dahl, Thobias | |
dc.contributor.author | Stormorken, Espen | |
dc.contributor.author | Anderson, Kristina | |
dc.contributor.author | Vo, Camilla Dao | |
dc.contributor.author | Schjesvold, Fredrik Hellem | |
dc.contributor.author | Myeloma Center, Oslo | |
dc.date.accessioned | 2020-08-28T09:15:22Z | |
dc.date.available | 2020-08-28T09:15:22Z | |
dc.date.created | 2018-11-20T12:24:58Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | BMC Cancer. 2018, 18:801 1-9. | en_US |
dc.identifier.issn | 1471-2407 | |
dc.identifier.uri | https://hdl.handle.net/11250/2675496 | |
dc.description.abstract | Background: With the advent of novel drugs improved overall survival in patients with multiple myeloma, including patients who received up-front autologous stem cell transplantation (ASCT), has been reported from several centers. Here we report on overall survival in a population-based cohort of patients receiving ASCT as first line treatment and in whom novel agents were an option for second and later lines of treatment.
Methods: Patients with multiple myeloma ≤ 65 years of age who were considered for ASCT from 01.01.2001-31.06.2005 (period 1) and from 01.07.2005 until 31.12.2009 (period 2) at Oslo University Hospital (OUH) were identified. Relevant data were collected from the patients' medical records.
Results: Altogether, 293/355 patients received ASCT. In all, median OS was 82.9 months in patients ≤ 60 years of age and 59.0 months in patients 61-65 years. For patients ≤ 60 years of age median OS increased from 70.6 months to 87.7 months (p = 0. 22) and median survival after start of second line therapy increased from 34.5 months to 46.5 months (p = 0.015) between the two periods. For patients 61-65 years of age median OS increased from 57.3 months to 61.2 months (p = 0. 87) and median survival after start of second line therapy was practically unchanged (32.6 months vs. 33.1 months (p = 0.97) between the periods. In patients ≤ 60 years of age salvage ASCT was used in 34% of the patients while in patients 61-65 years of age salvage ASCT was used in 7.3% of the patients. The use of salvage ASCT and novel drugs, as well as the number of treatment lines, were higher in patients ≤ 60 years of age and increased during the study period.
Conclusion: In patients ≤ 60 years of age an increased median OS of 17 months between the two periods were noted, but the difference failed to reach statistical significance. However, a statistically significant difference in median survival of 12 months after start of second line therapy was found in this age group, which may be explained by a more active second line treatment. In patients 61-65 years only a slight increase of survival, not statistically significant, was noted between the periods. | en_US |
dc.language.iso | eng | en_US |
dc.relation.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6083560/pdf/12885_2018_Article_4722.pdf | |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.subject | Autologous stem cell transplantation; | en_US |
dc.subject | Multiple myeloma; | en_US |
dc.subject | Novel drugs; | en_US |
dc.subject | Overall survival; | en_US |
dc.title | Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: A retrospective, population based analysis | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. | en_US |
dc.source.pagenumber | 1-9 | en_US |
dc.source.volume | 18:801 | en_US |
dc.source.journal | BMC Cancer | en_US |
dc.source.issue | 1 | en_US |
dc.identifier.doi | 10.1186/s12885-018-4722-x | |
dc.identifier.cristin | 1632592 | |
cristin.unitcode | 1991,3,0,0 | |
cristin.unitname | Div Gjøvik | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |